FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Vashington,	D.C. 20549	
-------------	------------	--

Washington,	D.C. 20549	
-------------	------------	--

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					10	r Sed	ction	30(h) of the	Investme	nt Co	mpany Act	ot 194	10								
1. Name ar ARCH	LC				uer Name and Ticker or Trading Symbol <u>m Therapeutics Inc.</u> [BEAM]							5. Relationship of Reporti (Check all applicable) Director			n(s) to Iss 10% C						
(Last) 8755 W. SUITE 1	HIGGINS	First) ROAD	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020									Officer (below)	give title		Other below)	(specify			
(Street)			60631		4. If	f Am	endn	ndment, Date of Original Filed (Month/Day/Year)						Line)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person						
(City)	(3	State)	(Zip)	Doriv	ativ	,, S		uritine Ac	auired.	Die	nosed (of or	Pone	aficially	Owned						
1. Title of Security (Instr. 3)			2	2. Transaction Date (Month/Day/Ye		ion 2/ Ex/Year) if		Deemed cution Date,	3. Transa Code (3. Transaction Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		(A) or	5. Amount		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Transactio (Instr. 3 an				(1113411 4)		
Common	Stock			02/10/2	2020	0			C ⁽¹⁾		4,121,	520	A	(1)	4,121,520				See footnote ⁽²⁾		
Common	Stock			02/10/	2020	0			C ⁽¹⁾		4,121,	4,121,519 A			4,121,519		.,519 I		See footnote ⁽³⁾		
			Table II - D					ities Acq warrants							wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3. Transaction Sate Sate Sate Sate Sate Sate Sate Sate		vative urities uired (A) isposed of Instr. 3, 4	f 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amou Securities Underly Derivative Securi (Instr. 3 and 4)			nderlying ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	ve Ownes For lally Or I	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)							
				Code	e v	,	(A)	(D)	Date Exercisal		Expiration Date	Title	N	mount or umber of hares		Transac (Instr. 4)					
Series A-1 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				1,338,000	(1)		(1)	Comi		,338,000	(1)	0		I	See footnote ⁽²⁾		
Series A-1 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				1,338,000	(1)		(1)	Comi		,338,000	(1)	0		I	See footnote ⁽³⁾		
Series A-2 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				2,750,336	(1)		(1)	Comi		,750,336	(1)	0		I	See footnote ⁽²⁾		
Series A-2 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				2,750,335	(1)		(1)	Comi		,750,335	(1)	0		I	See footnote ⁽³⁾		
Series B Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				33,184	(1)		(1)	Com: Sto		33,184	(1)	0		I	See footnote ⁽²⁾		
Series B Preferred Stock	(1)	02/10/2020		C ⁽¹⁾				33,184	(1)		(1)	Comi		33,184	(1)	0		I	See footnote ⁽³⁾		
		Reporting Person* Partners IX, I (First)	LLC (Middle)																		

8755 W. HIGGINS ROAD **SUITE 1025** (Street) **CHICAGO** 60631 (City) (State) (Zip) 1. Name and Address of Reporting Person* ARCH Venture Partners IX, L.P. (Middle) 8755 W. HIGGINS ROAD

SUITE 1025								
(Street) CHICAGO	IL	60631						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* <u>ARCH Venture Partners IX Overage, L.P.</u>								
(Last) 8755 W. HIGGINS SUITE 1025	(First) ROAD	(Middle)						
(Street) CHICAGO	IL	60631						
(City)	(State)	(Zip)						
1. Name and Address of ARCH Venture								
(Last) 8755 W. HIGGINS SUITE 1025	(First) ROAD	(Middle)						
(Street) CHICAGO	IL	60631						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* ARCH Venture Fund IX Overage, L.P.								
(Last) 8755 W. HIGGINS SUITE 1025	(First) ROAD	(Middle)						
(Street) CHICAGO	IL	60631						
(City)	(State)	(Zip)						
1. Name and Address of CRANDELL K								
(Last)	(First)	(Middle)						
	JRE PARTNERS IX, ROAD SUITE 1025	LLC						
	NOMD SCITE 1025							
(Street) CHICAGO	IL	60631						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* BYBEE CLINTON								
(Last)	(First)	(Middle)						
	JRE PARTNERS IX, ROAD SUITE 1025	LLC						
(Street) CHICAGO	IL	60631						
(City) Explanation of Response	(State)	(Zip)						

Explanation of Responses:

^{1.} Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series B Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock, Series A-2 Preferred Stock, or Series B Preferred Stock.

^{2.} These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

^{3.} These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be

deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Remarks:

By: ARCH Venture Partners IX, LLC, By: /s/ Mark McDonnell, 02/11/2020 as Attorney-in-Fact for Robert Nelsen, Managing Director By: ARCH Venture Partners IX, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark 02/11/2020 McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director By: ARCH Venture Partners IX Overage, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark 02/11/2020 McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director By: ARCH Venture Fund IX, L.P., By: ARCH Venture Partners IX, L.P., its General Partner, By: ARCH Venture Partners IX, LLC, its General 02/11/2020 Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing By: ARCH Venture Fund IX Overage, L.P., By: ARCH Venture Partners IX Overage, L.P., its General Partner, By: ARCH Venture Partners IX, 02/11/2020 LLC, its General Partner, By: /s/ Mark McDonnell, as Attorneyin-Fact for Keith Crandell, **Managing Director** By: Keith Crandell, Managing 02/11/2020 Director, By: /s/ Mark McDonnell, as Attorney-in-Fact By: Clinton Bybee, Managing 02/11/2020 Director, By: /s/ Mark McDonnell, as Attorney-in-Fact ** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.